These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11205458)

  • 21. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
    Beer TM; Bubalo JS
    Curr Urol Rep; 2002 Jun; 3(3):232-8. PubMed ID: 12084194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy for prostate cancer: finally an advance!
    Gulley J; Dahut WL
    Am J Ther; 2004; 11(4):288-94. PubMed ID: 15266221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.
    Pienta KJ
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):3-7. PubMed ID: 11685722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current chemotherapeutic approaches for androgen-independent prostate cancer.
    Rumohr JA; Chang SS
    Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of chemotherapy in advanced prostate cancer.
    Ernst DS
    Can J Urol; 2002 Jun; 9 Suppl 1():21-5. PubMed ID: 12121591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update in the management of patients with hormone-refractory prostate cancer.
    Moore CN; George DJ
    Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
    ; Berry DL; Moinpour CM; Jiang CS; Ankerst DP; Petrylak DP; Vinson LV; Lara PN; Jones S; Taplin ME; Burch PA; Hussain MH; Crawford ED
    J Clin Oncol; 2006 Jun; 24(18):2828-35. PubMed ID: 16782921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
    Collins R; Fenwick E; Trowman R; Perard R; Norman G; Light K; Birtle A; Palmer S; Riemsma R
    Health Technol Assess; 2007 Jan; 11(2):iii-iv, xv-xviii, 1-179. PubMed ID: 17181985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which drug combination for hormone-refractory prostate cancer?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel (taxotere) in the treatment of prostate cancer.
    Beer TM; El-Geneidi M; Eilers KM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.